E-ISSN 2367-699X | ISSN 2367-7414
 

Case Report 


INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind M'rabti, Hassan Errihani.

Abstract
Bevacizumab is a recombinant humanized monoclonal antibody targeting the vascular endothelial growth factor; it is actually approved for the treatment of unresectable, locally advanced and metastatic non-small cell lung cancer in association with chemotherapy and as maintenance therapy. Infection risk due to use of bevacizumab is a very rare event. Several cases of aspergillosis in patients treated with monoclonal antibodies have been reported, mostly following treatment with tumor necrosis factor alpha blockers. We present a case of a 60 year-old patient treated for stage IV non-small cell lung cancer, who has been diagnosed with invasive aspergillosis following bevacizumab treatment, and, we postulate that bevacizumab may contribute to this infection.

Key words: Invasive aspergillosis, Bevacizumab


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Khadija Bellahammou
Articles by Asmaa Lakhdissi
Articles by Akkar Othman
Articles by Salmi Narimane
Articles by Ibrahim El Ghissassi
Articles by Fadoua Rais
Articles by Naoual Benhmidou
Articles by Hind M'rabti
Articles by Hassan Errihani
on Google
on Google Scholar
Article Statistics
 Viewed: 2986
Downloaded: 445
Cited: 0


REFERENCES
1. Wagner L Nedel, Dimitrios P Kontoyiannis and Alessandro C. Pasqualotto. Aspergillosis in patients treated with monoclonal antibodies. Rev Iberoam Micol.2009; 26: 175-183. [DOI via Crossref]    [Pubmed]   
2. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications, Semin Oncol. 2002 Dec; 29: 10-4. [DOI via Crossref]    [Pubmed]   
3. Http: //www.cancer.gov/cancertopics/druginfo/FDA-bevacizumab.
4. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1; 22:2184-91. [DOI via Crossref]    [Pubmed]   
5. AnMM, Zou Z,Shen H, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab : an apdated meta-analysis. Eur J Clin Pharmacol 2010; 66 :813-21. [DOI via Crossref]    [Pubmed]   
6. Choueiri TK, Mayer El,Je Y,et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011 ; 29-632-8.
7. Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroups outcomes. Ann Oncol 2011; 22:1404-12. [DOI via Crossref]    [Pubmed]   
8. Hang XF, Xu WS, Wang GX and al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2011; 67:613-23. [DOI via Crossref]    [Pubmed]   
9. Zhu X, Wu S, Dahut WL,Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49:186-93. [DOI via Crossref]    [Pubmed]   
10. Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21 :1381-9. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
11. Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol 2014;70 :893-906. [DOI via Crossref]    [Pubmed]   
12. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009 ;10 :559-68. [DOI via Crossref]   
13. Wei-Xiang Qi, Shen Fua, Qing Zhang, Xiao-Mao Guo. Bevacizumab increases the risk of infections in cancer patients: Asystematic review and pooled analysis of 41 randomized controlled trials. Critical Reviews in Oncology/Hematology 2015; 94 323–336. [DOI via Crossref]    [Pubmed]   
14. Latgé JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12:310-50. [Pubmed]    [PMC Free Fulltext]   
15. Taylor, R. T. Dagenais and Nancy P. Keller. Pathogenesis of aspergillus fumigatus in invasive aspergillosis. Clinical Microbiology Reviews, July 2009, p. 447–465.
16. Filler SG, Sheppard DC. Fungal invasion of normally non-phagocytic host cells. PLoS Pathog 2006; 2:129. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
17. Kamai Y, Chiang LY, Lopes Bezerra LM, et al. Interactions of Aspergillus fumigatus with vascular endothelial cells. Med Mycol 2006; 44:115-7. [DOI via Crossref]    [Pubmed]   
18. Lopes Bezerra LM, Filler SG. Interactions of aspergillus fumigatus with endothelial cells: internalization, injury and stimulation of tissue factor activity. Blood 2004; 103:2143-9. [DOI via Crossref]    [Pubmed]   
19. Inoue K, Matsuyama W, Hashiguchi T,Wakimoto J,Hirotsu Y,Kawabata M,et al.Expression of vascular endothelial growth factor in pulmonary aspergilloma.Intern Med 2001 ;40 :1195-9. [DOI via Crossref]    [Pubmed]   
20. Sunderkotter C, Steinbrink K, Goebeler M and al. Macrophages and angiogenesis. J Leukoc Biol. 1994; 55:410–422. [Pubmed]   
21. Hansen W, Hutzler M, Abel S, et al. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med2012; 209:2001 [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
22. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer2013; 13:871–82. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
23. Kumagai H,Someno T,Dobashi K,Isshiki K,Ishizuka M,Ikeda D.ICM0301s, New angiogenesis inhibitors from aspergillus sp. F1491. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) 2004; 57:97-103. [DOI via Crossref]   
24. Ingber D,Fujita T,Kishimoto S,Sudo K,Kanamaru T, Brem H, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth.Nature 1990 ;348 :555-7. [DOI via Crossref]    [Pubmed]   
25. Udagawa T, Yuan J, Panigrahy D,Chang YH,Shah J,D'Amato RJ.Cytochalasin E,an epoxide containing aspergillus-derived fungal metabolite,inhibits angiogenesis and tumor growth.J Pharmacol Exp Ther 2000;294 :421-7. [Pubmed]   
26. Williams J,Lim R,Tambyah P.Invasive aspergillosis associated with bevacizumab ,a vascular endothelial growth factor inhibitor.Int J Infect Dis.2007 ;11 :549-50 . [DOI via Crossref]    [Pubmed]   
27. Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, et al. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   

How to Cite this Article
Pubmed Style

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind Mrabti, Hassan Errihani. INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER. Int J Surg Med. 2016; 2(3): 187-189. doi:10.5455/ijsm.invasive-pulmonary-aspergillosis


Web Style

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind Mrabti, Hassan Errihani. INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER. http://www.ejos.org/?mno=225447 [Access: June 19, 2019]. doi:10.5455/ijsm.invasive-pulmonary-aspergillosis


AMA (American Medical Association) Style

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind Mrabti, Hassan Errihani. INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER. Int J Surg Med. 2016; 2(3): 187-189. doi:10.5455/ijsm.invasive-pulmonary-aspergillosis



Vancouver/ICMJE Style

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind Mrabti, Hassan Errihani. INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER. Int J Surg Med. (2016), [cited June 19, 2019]; 2(3): 187-189. doi:10.5455/ijsm.invasive-pulmonary-aspergillosis



Harvard Style

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind Mrabti, Hassan Errihani (2016) INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER. Int J Surg Med, 2 (3), 187-189. doi:10.5455/ijsm.invasive-pulmonary-aspergillosis



Turabian Style

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind Mrabti, Hassan Errihani. 2016. INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER. International Journal of Surgery and Medicine, 2 (3), 187-189. doi:10.5455/ijsm.invasive-pulmonary-aspergillosis



Chicago Style

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind Mrabti, Hassan Errihani. "INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER." International Journal of Surgery and Medicine 2 (2016), 187-189. doi:10.5455/ijsm.invasive-pulmonary-aspergillosis



MLA (The Modern Language Association) Style

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind Mrabti, Hassan Errihani. "INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER." International Journal of Surgery and Medicine 2.3 (2016), 187-189. Print. doi:10.5455/ijsm.invasive-pulmonary-aspergillosis



APA (American Psychological Association) Style

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind Mrabti, Hassan Errihani (2016) INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER. International Journal of Surgery and Medicine, 2 (3), 187-189. doi:10.5455/ijsm.invasive-pulmonary-aspergillosis